rethinkTHC Search
Menu
Study breakdown

Medical Cannabis Patients Stopped Using Dangerous Prescription Drugs at High Rates

Retrospective CohortModerate evidence
The takeaway

After enrolling in New Mexico's medical cannabis program, 34% of chronic pain patients completely stopped using all scheduled prescription medications, compared to only 2% in a comparison group.

Pain management providers, medical cannabis policy makers, chronic pain patients.

34% of medical cannabis patients stopped all scheduled prescription medications vs 2% of comparison patients.

What the researchers found

28 of 83 MCP patients (34%) ceased all scheduled prescription medications by the end of the observation period, versus only 1 of 42 comparison patients (2%). MCP patients showed statistically significant monthly decreases in number of prescriptions, distinct drug classes, prescription fill dates, and prescribing providers.

Why it matters

Co-prescribing of controlled substances (Schedule II-V) is a major safety concern and healthcare burden. This study provides some of the first Prescription Monitoring Program data showing medical cannabis enrollment is associated with significant reductions in dangerous prescription drug use.

The numbers in context

34% of MCP patients stopped all scheduled drugs vs 2% of comparisons. Significant monthly decreases in all 4 measures (counts of -0.02 to -0.04, P values <.001 to .017). Differences were significant by 10 months post-enrollment.

How the study worked

Pragmatic historical cohort study comparing 83 chronic pain patients who enrolled in New Mexico's Medical Cannabis Program with 42 non-enrolled patients over 24 months using Prescription Monitoring Program data.

What this study cannot tell us

Observational study with non-randomized groups. Comparison group was small (n=42). Cannot confirm patients actually used cannabis or that cannabis caused the prescription changes. New Mexico-specific results.

How to read the evidence

Moderate - uses objective Prescription Monitoring Program data, but observational with non-randomized comparison group.

When this study was published

Published in 2018. Data from 2010-2015.

The bigger picture

If medical cannabis can reduce reliance on dangerous prescription medications, particularly opioids, it could address two crises simultaneously: the opioid epidemic and the broader problem of polypharmacy with controlled substances.

Questions still open

  • Which specific drug classes were most reduced? Did patients maintain symptom control after stopping prescriptions? Would these results replicate in states with different medical cannabis program structures?

Common questions

Can medical cannabis replace prescription drugs?
In this study, 34% of chronic pain patients who enrolled in New Mexico's medical cannabis program completely stopped using all scheduled prescription medications within 18 months, compared to only 2% of similar patients who did not enroll.
Does medical cannabis reduce opioid use?
This study showed significant reductions in all scheduled drug prescriptions (including opioids) after medical cannabis enrollment, with decreases becoming statistically significant by 10 months. However, it could not determine which specific drug classes were most affected.

Read the original research

Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions.

Journal of the American Medical Directors Association, 19(1), 59-64.e1

Citation

Stith, Sarah S; Vigil, Jacob M; Adams, Ian Marshall; Reeve, Anthony P. (2018). Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions.. Journal of the American Medical Directors Association, 19(1), 59-64.e1. https://doi.org/10.1016/j.jamda.2017.07.017

Explore the wider topic